Current status of PET imaging in neuro-oncology. Issue 1 (28th May 2019)

• Record Type: Journal Article
• Authors: Galldiks, Norbert; Lohmann, Philipp; Albert, Nathalie L; Tonn, Jörg C; Langen, Karl-Josef
• Is Part Of: Neuro-oncology advances. Volume 1:Issue 1(2019)
• Publication Date: 2019-05-28
• Subjects: DOTATOC -- DOTATATE -- FDOPA -- FDG -- FET -- FLT -- MRI -- positron emission tomography; 616.99481
• DOI: 10.1093/noajnl/vdz010
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Over the past decades, a variety of PET tracers have been used for the evaluation of patients with brain tumors. For clinical routine, the most important clinical indications for PET imaging in patients with brain tumors are the identification of neoplastic tissue including the delineation of tumor extent for the further diagnostic and therapeutic management (ie, biopsy, resection, or radiotherapy planning), the assessment of response to a certain anticancer therapy including its (predictive) effect on the patients' outcome and the differentiation of treatment-related changes (eg, pseudoprogression and radiation necrosis) from tumor progression at follow-up. To serve medical professionals of all disciplines involved in the diagnosis and care of patients with brain tumors, this review summarizes the value of PET imaging for the latter-mentioned 3 clinically relevant indications in patients with glioma, meningioma, and brain metastases.